Cargando…
Combination Therapy Comprising Paclitaxel and 5-Fluorouracil by Using Folic Acid Functionalized Bovine Milk Exosomes Improves the Therapeutic Efficacy against Breast Cancer
Paclitaxel (PAC) has been approved by FDA for clinical use (Taxol(®)), yet dose-dependent severe toxicity due to the adjuvant Cremophor EL(®) in combination with ethanol is a major drawback. The drawbacks of the current therapy can be overcome by (i) finding a suitable vehicle that cannot only bypas...
Autores principales: | Kumar, Dulla Naveen, Chaudhuri, Aiswarya, Dehari, Deepa, Shekher, Anusmita, Gupta, Subash C., Majumdar, Shreyasi, Krishnamurthy, Sairam, Singh, Sanjay, Kumar, Dinesh, Agrawal, Ashish Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410314/ https://www.ncbi.nlm.nih.gov/pubmed/36013322 http://dx.doi.org/10.3390/life12081143 |
Ejemplares similares
-
Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023) -
Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
por: Chaudhuri, Aiswarya, et al.
Publicado: (2022) -
A Bacteriophage Microgel Effectively Treats the Multidrug-Resistant Acinetobacter baumannii Bacterial Infections in Burn Wounds
por: Dehari, Deepa, et al.
Publicado: (2023) -
Exosomes as Emerging Drug Delivery and Diagnostic Modality for Breast Cancer: Recent Advances in Isolation and Application
por: Kumar, Dulla Naveen, et al.
Publicado: (2022) -
Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy
por: Chaudhuri, Aiswarya, et al.
Publicado: (2022)